Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Panbela Therapeutics Inc (NQ: PBLA )

6.580 +0.220 (+3.46%)
Streaming Delayed Price Updated: 4:00 PM EDT, Jun 2, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Panbela Therapeutics Inc

< Previous 1 2 Next >
Panbela Announces Poster Presentation at Immunology of Diabetes Society Meeting: Evaluating the Potential of CPP-1X (Eflornithine) in Recent Onset Type 1 Diabetes
From Panbela Therapeutics, Inc.
Via GlobeNewswire
Panbela Announces 1-for-30 Reverse Stock Split Effective June 1, 2023
From Panbela Therapeutics, Inc.
Via GlobeNewswire
Panbela Announces Clinical Trial with Moffitt Cancer Center for Phase I/II Program in STK11 Mutant Non-Small Cell Lung Cancer
From Panbela Therapeutics, Inc.
Via GlobeNewswire
Panbela to Host First Quarter 2023 Earnings Conference Call on May 4, 2023
From Panbela Therapeutics, Inc.
Via GlobeNewswire
Panbela Announces Poster Presentation at American Association for Cancer Research: Evaluating the potential of spermine analogue ivospemin (SBP-101) in combination with chemotherapy in ovarian cancer
From Panbela Therapeutics, Inc.
Via GlobeNewswire
First Patient Enrolled in JDRF-Funded Phase II Trial of CPP-1X-T for Recent Onset Type I Diabetes, Led by Indiana University School of Medicine
From Panbela Therapeutics, Inc.
Via GlobeNewswire
Panbela Regains Worldwide Rights to Develop and Commercialize FlynpoviTM in Patients with Familial Adenomatous Polyposis (FAP)
From Panbela Therapeutics, Inc.
Via GlobeNewswire
Acceptance of CPP-1X (DFMO) Abstract for Poster Presentation at Immunology of Diabetes Society Meeting
From Panbela Therapeutics, Inc.
Via GlobeNewswire
Acceptance of CPP-1X (DFMO) Abstract for Poster Presentation at Endocrine Society Meeting
From Panbela Therapeutics, Inc.
Via GlobeNewswire
Panbela Announces New Research Agreement with Johns Hopkins University School of Medicine
From Panbela Therapeutics, Inc.
Via GlobeNewswire
Panbela Announces Issuance of New Patent in Japan; Patent is for Claims of a Novel Process for the Production of SBP-101
Patent developed in collaboration with Syngene International Ltd. 
From Panbela Therapeutics, Inc.
Via GlobeNewswire
Panbela to Host Fourth Quarter and Year End 2022 Earnings Conference Call on March 16, 2023
From Panbela Therapeutics, Inc.
Via GlobeNewswire
Panbela Announces First Patient Enrolled in South Korea for ASPIRE Trial Studying Ivospemin (SBP-101) in Combination with Gemcitabine and Nab-Paclitaxel in Patients with Metastatic Pancreatic Ductal Adenocarcinoma
From Panbela Therapeutics, Inc.
Via GlobeNewswire
Acceptance of SBP-101 Abstract for Poster Presentation at American Association for Cancer Research (AACR)
From Panbela Therapeutics, Inc.
Via GlobeNewswire
Panbela Announces Closing of Approximately $15 Million Public Offering, and Regains Compliance with Nasdaq Listing Standards
From Panbela Therapeutics, Inc.
Via GlobeNewswire
Panbela Announces Pricing of Approximately $15 Million Public Offering
From Panbela Therapeutics, Inc.
Via GlobeNewswire
Panbela Announces Adoption of Commission Implementing Decision from the EMA for the Orphan Designation of Ivospemin (SBP-101) in Combination with Gemcitabine and Nab-Paclitaxel in Patients with Metastatic Pancreatic Ductal Adenocarcinoma
From Panbela Therapeutics, Inc.
Via GlobeNewswire
Panbela Announces 1-for-40 Reverse Stock Split effective January 13, 2023
From Panbela Therapeutics, Inc.
Via GlobeNewswire
Panbela Starts Phase II Trial of CPP-1X-T for Recent Onset Type I Diabetes, in Collaboration with Indiana University School of Medicine and JDRF
From Panbela Therapeutics, Inc.
Via GlobeNewswire
Panbela Receives Positive EMA Opinion on Orphan Designation for Ivospemin (SBP-101) in Combination with Gemcitabine and Nab-Paclitaxel in Patients with Metastatic Pancreatic Ductal Adenocarcinoma
From Panbela Therapeutics, Inc.
Via GlobeNewswire
Panbela Announces First Patients Enrolled in Europe for ASPIRE Trial Studying Ivospemin (SBP-101) in Combination with Gemcitabine and Nab-Paclitaxel in Patients with Metastatic Pancreatic Ductal Adenocarcinoma
From Panbela Therapeutics, Inc.
Via GlobeNewswire
Panbela Schedules Conference Call on, November 10, 2022, to Report 2022 Third Quarter Financial Results
From Panbela Therapeutics, Inc.
Via GlobeNewswire
InvestorNewsBreaks – Panbela Therapeutics Inc. (NASDAQ: PBLA) Reports on $6M Closed Offering
Via Investor Brand Network
Panbela to Participate in the Roth Inaugural Healthcare Opportunities Conference
From Panbela Therapeutics, Inc.
Via GlobeNewswire
Panbela Announces Pricing of Approximately $6 Million Public Offering
From Panbela Therapeutics, Inc.
Via GlobeNewswire
Panbela Receives Approvals to Open Trial Sites in Spain, France and Italy for ASPIRE Trial Studying Ivospemin (SBP-101) in Combination with Gemcitabine and Nab-Paclitaxel in Patients with Metastatic Pancreatic Ductal Adenocarcinoma
From Panbela Therapeutics, Inc.
Via GlobeNewswire
PANBELA THERAPEUTICS INVESTOR ALERT - Kuznicki Law PLLC Investigates Panbela Therapeutics, Inc. - PBLA
From Kuznicki Law PLLC
Via Business Wire
PANBELA THERAPEUTICS INVESTOR ALERT by The Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Panbela Therapeutics, Inc. - PBLA
From Kahn Swick & Foti, LLC
Via Business Wire
PANBELA THERAPEUTICS INVESTOR ALERT By The Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Panbela Therapeutics, Inc. - PBLA
From Kahn Swick & Foti
Via Business Wire
PBLA Stock Investigation: Halper Sadeh LLP Is Investigating Whether the Merger of Panbela Therapeutics, Inc. Is Fair to Shareholders
From Halper Sadeh LLP
Via Business Wire
< Previous 1 2 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.